大阪で最高の長寿科医師 - トップ2名の医師

As a specialist at the clinic, Dr. Eric Verdin (President of the Buck Institute for Research on Aging) is referenced in the clinic’s NAD+ discussion for why intravenous NAD+ may not reach cells effectively. In a conversation with Peter Attia on The Drive (episode #359), he highlighted NAD+’s molecular size and described breakdown into nicotinamide before cellular use. The clinic’s longevity messaging therefore leans toward oral precursors like NMN as a more workable option.

As a specialist at the clinic, Dr. Yuichi Wakabayashi (M.D., Ph.D., ABRM Diplomate) directs regenerative medicine and personally reviews every international enquiry. He has personally managed 3,000+ stem cell cases across ~20 countries and personally conducts the full treatment workflow, from mini adipose harvesting to follow-up at 1/3/6 months. The clinic’s protocols are built around ~7-week CPC cultivation with viability testing reported as 98%+ and 13 government-approved treatment plans.